Patient-Focused Drug Development (PFDD) meeting with the FDA for GM2 Gangliosidosis 

Our friends at the National Tay-Sachs & Allied Diseases Association have been able to secure a Patient-Focused Drug Development (PFDD) meeting with the FDA! The event is only a few weeks away on Feb. 15, 2024 and starts at 9:30 am ET.

This is an amazing opportunity for our Tay-Sachs and Sandhoff community to inform the FDA and key stakeholders on the experiences we all face living with the diseases.

👇 All are welcome and if you haven’t yet, register now👇
https://lnkd.in/dtjGdtCG

⭐ Are you part of the GM2 community, but unable to attend the meeting? You can still share your knowledge by submitting an early comment below⭐

If you have any questions please reach out to us at the charity.